2.41
+0.28(+13.15%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
98
First IPO Date
July 13, 2021
| Name | Title | Pay | Year Born |
| Dr. Zhi Hong Ph.D. | Co-founder, Executive Chairman of the Board & Chief Executive Officer | 16.08M | 1964 |
| Dr. Ankang Li C.F.A., J.D., Ph.D. | Chief Financial & Strategy Officer, Joint Secretary and Executive Director | 7.1M | 1979 |
| Ms. Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources | 0 | 1977 |
| Dr. Brian Alvin Johns Ph.D. | Chief Scientific Officer | 0 | N/A |
| Dr. David Margolis M.D., M.P.H. | Chief Medical Officer | 0 | 1976 |
| Dr. Qing Zhu Ph.D. | Head of China Research & Development | 0 | 1969 |
| Ms. Wing Tsz Ho CGP, FCIS, FCS, M.B.A., P.E. | Joint Company Secretary | 0 | 1970 |
| Dr. Susannah Cantrell Ph.D. | Chief Business Officer | 0 | 1969 |
| Sarah Qiu | Associate Director of Investor Relations | 0 | N/A |
| Dr. Eleanor de Groot Ph.D. | Chief Technology Officer | 0 | 1969 |
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.